When a thymic carcinoma " becomes" a GIST

Lung Cancer

Volumn 80, Issue 1, 2013, Pages 106-108

  Rossi, Valentina ^a   Donini, Maddalena ^a   Sergio, Pietro ^a   Passalacqua, Rodolfo ^a   Rossi, Giulio ^b   Buti, Sebastiano ^c  

^a Istituti Ospitalieri of Cremona ^*  (Italy)

^b S MARIA NUOVA HOSPITAL   (Italy)

^c UNIVERSITY HOSPITAL OF PARMA   (Italy)

Author keywords

C Kit; Carcinoma; GIST; Imatinib; Sunitinib; Thymic

Indexed keywords

IMATINIB; SUNITINIB;

ADULT; ARTICLE; ASTHENIA; CANCER CHEMOTHERAPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DISEASE COURSE; DISEASE SEVERITY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; GASTROINTESTINAL STROMAL TUMOR; HUMAN; LIVER METASTASIS; LUNG METASTASIS; MALE; MISSENSE MUTATION; OUTCOME ASSESSMENT; PLEURA EFFUSION; PRIORITY JOURNAL; THORAX PAIN; THYMUS CANCER; TREATMENT DURATION; TREATMENT FAILURE; TUMOR BIOPSY;

ANTINEOPLASTIC AGENTS; BENZAMIDES; GASTROINTESTINAL STROMAL TUMORS; HUMANS; INDOLES; MALE; MIDDLE AGED; MUTATION; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; PYRROLES; THYMOMA; THYMUS NEOPLASMS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84875273453     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.01.003     Document Type: Article

References (24)

1. Eng T.Y., Fuller C.D., Jagirdar J., Bains Y., Thomas C.R. Thymic carcinoma: state of the art review. Int J Radiat Oncol Biol Phys 2004, 59(Jul 1 (3)):654-664.
2. Wright C.D., Kessler K.A. Surgical treatment of thymic tumors. Semin Thorac Cardiovasc Surg 2005, 17(Spring (1)):20-26.
3. Loehrer P.J., Kim K., Aisner S.C., Livingston R., Einhorn L.H., Johnson D., et al. Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group. J Clin Oncol 1994, 12(Jun (6)):1164-1168.
4. Evans T.L., Lynch T.J. Role of chemotherapy in the management of advanced thymic tumors. Semin Thorac Cardiovasc Surg 2005, 17(Spring (1)):41-50.
5. Moran C.A., Suster S. On the histologic heterogeneity of thymic epithelial neoplasms, impact of sampling in subtyping and classification of thymomas. Am J Clin Pathol 2000, 114(Nov (5)):760-766.
6. Schirosi L., Nannini N., Nicoli D., Cavazza A., Valli R., Buti S., et al. Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors. Ann Oncol 2012, 23(Sep (9)):2409-2414.
7. Farina G., Garassino M.C., Gambacorta M., La V.N., Gherardi G., Scanni A. Response of thymoma to cetuximab. Lancet Oncol 2007, 8(May (5)):449-450.
8. Kurup A., Burns M., Dropcho S. Phase II trial of gefitinib treatment in advanced thymic malignancies. J Clin Oncol 2005, 23:381s. abstract 7068.
9. Giaccone G., Rajan A., Berman A., Kelly R.J., Szabo E., Lopez-Chavez A., et al. Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors. J Clin Oncol 2011, 29(May 20 (15)):2052-2059.
10. Ferone D., van Hagen P.M., van Koetsveld P.M., Zuijderwijk J., Mooy D.M., Lichtenauer-Kaligis E.G., et al. In vitro characterization of somatostatin receptors in the human thymus and effects of somatostatin and octreotide on cultured thymic epithelial cells. Endocrinology 1999, 140(Jan (1)):373-380.
11. Loehrer P.J., Wang W., Johnson D.H., Aisner S.C., Ettinger D.S. Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: an Eastern Cooperative Oncology Group Phase II Trial. J Clin Oncol 2004, 22(Jan 15 (2)):293-299.
12. Arun Rajan, Riely Gregory J., Corey Allan Carte, et al. Phase II study of cixutumumab (IMC-A12) in thymic malignancies. J Clin Oncol 2012, (Jun 30 (Suppl)). abstract 7033.
13. Cimpean A.M., Raica M., Encica S., Cornea R., Bocan V. Immunohistochemical expression of vascular endothelial growth factor A (VEGF), and its receptors (VEGFR1, 2) in normal and pathologic conditions of the human thymus. Ann Anat 2008, 190(3):238-245.
14. Tomita M., Matsuzaki Y., Edagawa M., Maeda M., Shimizu T., Hara M., et al. Correlation between tumor angiogenesis and invasiveness in thymic epithelial tumors. J Thorac Cardiovasc Surg 2002, 124(Sep (3)):493-498.
15. Bisagni G., Rossi G., Cavazza A., Sartori G., Gardini G., Boni C. Long lasting response to the multikinase inhibitor bay 43-9006 (sorafenib) in a heavily pretreated metastatic thymic carcinoma. J Thorac Oncol 2009, 4(Jun (6)):773-775.
16. Li X.F., Chen Q., Huang W.X., Ye Y.B. Response to sorafenib in cisplatin-resistant thymic carcinoma: a case report. Med Oncol 2009, 26(2):157-160.
17. Strobel P., Bargou R., Wolff A., Spitzer D., Manegold C., Dimitrakopoulou-Strauss A., et al. Sunitinib in metastatic thymic carcinomas: laboratory findings and initial clinical experience. Br J Cancer 2010, 103(Jul 13 (2)):196-200.
18. Giaccone G., Rajan A., Ruijter R., Smit E., van G.C., Hogendoorn P.C. Imatinib mesylate in patients with WHO B3 thymomas and thymic carcinomas. J Thorac Oncol 2009, 4(Oct (10)):1270-1273.
19. Strobel P., Hartmann M., Jakob A., Mikesch K., Brink I., Dirnhofer S., et al. Thymic carcinoma with overexpression of mutated KIT and the response to imatinib. N Engl J Med 2004, 350(Jun 17 (25)):2625-2626.
20. Yoh K., Nishiwaki Y., Ishii G., Goto K., Kubota K., Ohmatsu H., et al. Mutational status of EGFR and KIT in thymoma and thymic carcinoma. Lung Cancer 2008, 62(Dec (3)):316-320.
21. Girard N. Thymic tumors: relevant molecular data in the clinic. J Thorac Oncol 2010, 5(Oct (10 Suppl 4)):S291-S295.
22. Disel U., Oztuzcu S., Besen A.A., Karadeniz C., Kose F., Sumbul A.T., et al. Promising efficacy of sorafenib in a relapsed thymic carcinoma with C-KIT exon 11 deletion mutation. Lung Cancer 2011, 71(Jan (1)):109-112.
23. Buti S., Donini M., Sergio P., Garagnani L., Schirosi L., Passalacqua R., et al. Impressive response with imatinib in a heavily pretreated patient with metastatic c-KIT mutated thymic carcinoma. J Clin Oncol 2011, 29(Nov 20 (33)):e803-e805.
24. Demetri G.D., van Oosterom A.T., Garrett C.R., Blackstein M.E., Shah M.H., Verweij J., et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006, 368(Oct 14 (9544)):1329-1338.